Showing results (471-480 of 635) with videos related to

Sort By:
Pageof 64
Clinical Cardiology|November 15, 2019
Rationale and design of a navigator-driven remote optimization of guideline-directed medical therapy in patients with heart failure with reduced ejection fractionAlexander J Blood, Christina M Fischer, Liliana E Fera, et al.
European Heart Journal|May 21, 2023
Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HFMuthiah Vaduganathan, Robert J Mentz, Brian L Claggett, et al.
JAMA Cardiology|August 13, 2025
Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical TrialMisato Chimura, Pardeep S Jhund, Alasdair D Henderson, et al.
Circulation|June 29, 2026
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)Mary Norine Walsh, Lars Kober, Karen Sliwa, et al.
Journal of the American College of Cardiology|November 7, 2015
Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HFJoanne Simpson, Pardeep S Jhund, Jose Silva Cardoso, et al.
Population Health Management|December 4, 2024
Identifying Patients with Heart Failure Eligible for Guideline-Directed Medical TherapySamantha Subramaniam, Shahzad Hassan, Ozan Unlu, et al.
European Journal of Heart Failure|October 3, 2025
Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: Findings from FINEARTS-HFJoão Pedro Ferreira, Muthiah Vaduganathan, Brian L Claggett, et al.
JAMA Cardiology|October 3, 2022
Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical TrialMuthiah Vaduganathan, Brian L Claggett, Pardeep Jhund, et al.
Circulation. Heart Failure|April 18, 2018
Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure TrialEldrin F Lewis, Brian Claggett, Amil M Shah, et al.
JAMA Cardiology|March 28, 2026
EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial: A Prespecified Secondary Analysis of FINEARTS-HFMisato Chimura, Kirsty McDowell, Pardeep S Jhund, et al.
Pageof 64